FDA Accepts for Review Ibrutinib's sNDA for cGVHD

Share this content:
The FDA accepted for review a supplemental New Drug Application for ibrutinib as a treatment for chronic graft-versus-host-disease.
The FDA accepted for review a supplemental New Drug Application for ibrutinib as a treatment for chronic graft-versus-host-disease.

The US Food and Drug Administration (FDA) will review a supplemental New Drug Application (sNDA) for ibrutinib as a treatment of chronic graft-versus-host-disease (cGVHD) after the failure of steroid therapy, according to a press release.1

cGHVD is a potentially fatal condition that can arise after allogeneic stem cell transplant. It occurs in about 30% to 70% of patients, and is usually treated with a corticosteroid. There has, however, been a lack of FDA-approved alternatives if steroid-therapy fails.

Ibrutinib, a Bruton's kinase inhibitor, was evaluated as a second-line therapy for patients with cGVHD in a phase 1b/2 trial (ClinicalTrials.gov Identifier: NCT02195869), from which data were presented at the 2016 American Society of Hematology Annual Meeting.2

The overall response rate in this study was 67%, with a complete response rate of 21%.

In an ongoing, placebo-controlled, phase 3 trial (ClinicalTrials.gov Identifier: NCT02959944), researchers are evaluating the efficacy and safety of ibrutinib and prednisone as a combination first-line therapy.

RELATED: Ibrutinib for the Relief of GVHD-related Symptoms

Common adverse events among patients with B cell malignancies treated with ibrutinib include “neutropenia, thrombocytopenia, diarrhea, anemia, musculoskeletal pain, rash, nausea, bruising, fatigue, hemorrhage, and pyrexia.”

References

  1. U.S. FDA accepts for review the application of ibrutinib (IMBRUVICA®) for chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy [news release]. Raritan, NJ: Janssen; April 4, 2017. http://www.prnewswire.com/news-releases/us-fda-accepts-for-review-the-application-of-ibrutinib-imbruvica-for-chronic-graft-versus-host-disease-cgvhd-after-failure-of-one-or-more-lines-of-systemic-therapy-300434062.html?tc=eml_cleartime. Accessed April 4, 2017.
  2. Miklos D, Cutler CS, Arora M, et al. Multicenter open-label phase 2 study of ibrutinib in chronic graft versus host disease (cGVHD) after failure of corticosteroids. Paper presented at: American Society of Hematology 58th Annual Meeting and Exposition; December 3-6, 2016; San Diego, CA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters